Clinical DataVivani announced positive preclinical data for NPM-139, a subdermal implant being developed for chronic weight management, which demonstrated continuous and steady semaglutide exposure.
Financial PositionThe company closed two equity financings, resulting in a pro forma cash position of approximately $24.8M, providing a cash runway to mid-2026.
Market PotentialThe GLP-1 and obesity treatment market is expanding and can accommodate multiple players, offering opportunities for Vivani's platform.